Download the newest flash player in order to view the content. If you have the newest flash player installed please make sure javascript is enabled in your browser.

Ascending delivery: The CONCERTA® difference

Like some other ADHD medications, the active ingredient in CONCERTA® is methylphenidate, a time-tested, patient-proven ADHD therapy. The delivery of methylphenidate from CONCERTA® is what makes it different from every other ADHD medication.

CONCERTA® provides patented ascending delivery of methylphenidate, resulting in smooth plasma levels through 12 hours.

Ascending delivery of methylphenidate: CONCERTA® helps avoid the peaks and troughs seen with immediate-release medications1

  • The pharmacokinetic profiles from a three-way crossover study in 15 children with ADHD aged 7 to 12 years comparing immediate-release methylphenidate and CONCERTA®
  • Ascending delivery helps eliminate peaks and troughs associated with immediate-release medication1

References: 1. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003;60:204-211. 2. Pelham WE, Gnagy EM, Burrows-Maclean L, et al. Once-a-day Concerta methylphenidate versus three-times daily methylphenidate in laboratory natural settings. Pediatrics. 2001;107(6). Available at: http://www.pediatrics.org/cgi/content/full/107/6/e105.

CONCERTA® is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

IMPORTANT SAFETY INFORMATION

CONCERTA® should not be taken by patients with: allergies to methylphenidate or other ingredients in CONCERTA®; significant anxiety, tension, or agitation; glaucoma; Tourette's syndrome, tics, or family history of Tourette's syndrome; current or recent use of monoamine oxidase inhibitors (MAOIs). Children under 6 years of age should not take CONCERTA.®

Abuse of methylphenidate may lead to dependence. CONCERTA® should not be used in patients with known structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, other serious cardiac problems, or patients with pre-existing severe gastrointestinal narrowing. Use with caution in patients with hypertension and other cardiovascular conditions, psychosis, bipolar disorder, and history of seizures/EEG abnormalities. Stimulants may cause new psychotic or manic symptoms; discontinuation of treatment may be appropriate. Aggressive behavior or hostility should be monitored in patients beginning ADHD treatment. Methylphenidate may produce difficulties with visual accommodation and blurring of vision. Hematologic monitoring is advised during prolonged therapy. Growth should be monitored during treatment with stimulants, and patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted.

The most common adverse reaction (>5%) reported in children and adolescents was abdominal pain upper. The most common adverse reactions (>10%) reported in adults were dry mouth, nausea, decreased appetite, headache, and insomnia.

Please see full U.S. Prescribing Information

© Ortho-McNeil-Janssen Pharmaceuticals, Inc. 2010. All rights reserved. Your use of the information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy. This site is published by McNeil Pediatrics™, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. which is solely responsible for its contents.

This information is intended for the use of our customers and healthcare professionals in the United States and Puerto Rico only. McNeil Pediatrics™ recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may be not be appropriate for use outside the United States and Puerto Rico.

CONCERTA® and OROS® are registered trademarks of ALZA Corporation © Ortho-McNeil-Janssen Pharmaceuticals, Inc. Titusville, NJ, USA. All rights reserved.

McNeil Pediatrics Logo



Last Modified Date: Jun 15 2010 at 16:01:16 EDT